NCT00932802View on ClinicalTrials.gov

Greatest International Antiinfective Trial With Avelox

CompletedOBSERVATIONAL
Enrollment

50,000

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Bronchitis, ChronicBronchial Diseases
Interventions
DRUG

Moxifloxacin (Avelox, BAY12-8039)

AECB patients under daily life treatment receiving moxifloxacin according to the local product information.

Trial Locations (24)

Unknown

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00932802 - Greatest International Antiinfective Trial With Avelox | Biotech Hunter | Biotech Hunter